TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07479485: An Open-Label, Multicenter, Phase I/II Study Evaluating MRG006A in Combination With Immune Checkpoint Inhibitors and Targeted Therapy in Patients With Advanced Hepatocellular Carcinoma

Sponsor: Lepu Biopharma Co., Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 160 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,977,350

Rescue Site Savings

+$7,893,270

Unlock Full NCT07479485 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07479485 Rescue Dossier →